246 related articles for article (PubMed ID: 16094621)
1. Soluble MICA in malignant diseases.
Holdenrieder S; Stieber P; Peterfi A; Nagel D; Steinle A; Salih HR
Int J Cancer; 2006 Feb; 118(3):684-7. PubMed ID: 16094621
[TBL] [Abstract][Full Text] [Related]
2. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA.
Holdenrieder S; Stieber P; Peterfi A; Nagel D; Steinle A; Salih HR
Cancer Immunol Immunother; 2006 Dec; 55(12):1584-9. PubMed ID: 16636811
[TBL] [Abstract][Full Text] [Related]
3. Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism.
Holdenrieder S; Eichhorn P; Beuers U; Samtleben W; Stieber P; Nagel D; Peterfi A; Steinle A; Salih HR
Anticancer Res; 2007; 27(4A):2041-5. PubMed ID: 17649819
[TBL] [Abstract][Full Text] [Related]
4. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions.
Arreygue-Garcia NA; Daneri-Navarro A; del Toro-Arreola A; Cid-Arregui A; Gonzalez-Ramella O; Jave-Suarez LF; Aguilar-Lemarroy A; Troyo-Sanroman R; Bravo-Cuellar A; Delgado-Rizo V; Garcia-Iglesias T; Hernandez-Flores G; Del Toro-Arreola S
BMC Cancer; 2008 Jan; 8():16. PubMed ID: 18208618
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer.
Duan X; Deng L; Chen X; Lu Y; Zhang Q; Zhang K; Hu Y; Zeng J; Sun W
Med Oncol; 2011 Jun; 28(2):466-74. PubMed ID: 20354827
[TBL] [Abstract][Full Text] [Related]
6. Increased Concentrations of Circulating Soluble MHC Class I-Related Chain A (sMICA) and sMICB and Modulation of Plasma Membrane MICA Expression: Potential Mechanisms and Correlation With Natural Killer Cell Activity in Systemic Lupus Erythematosus.
Hervier B; Ribon M; Tarantino N; Mussard J; Breckler M; Vieillard V; Amoura Z; Steinle A; Klein R; Kötter I; Decker P
Front Immunol; 2021; 12():633658. PubMed ID: 34012432
[TBL] [Abstract][Full Text] [Related]
7. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
Waldhauer I; Steinle A
Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
[TBL] [Abstract][Full Text] [Related]
8. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas.
Jinushi M; Takehara T; Tatsumi T; Hiramatsu N; Sakamori R; Yamaguchi S; Hayashi N
J Hepatol; 2005 Dec; 43(6):1013-20. PubMed ID: 16168521
[TBL] [Abstract][Full Text] [Related]
9. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.
Salih HR; Antropius H; Gieseke F; Lutz SZ; Kanz L; Rammensee HG; Steinle A
Blood; 2003 Aug; 102(4):1389-96. PubMed ID: 12714493
[TBL] [Abstract][Full Text] [Related]
10. MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.
Zingoni A; Vulpis E; Cecere F; Amendola MG; Fuerst D; Saribekyan T; Achour A; Sandalova T; Nardone I; Peri A; Soriani A; Fionda C; Mariggiò E; Petrucci MT; Ricciardi MR; Mytilineos J; Cippitelli M; Cerboni C; Santoni A
Front Immunol; 2018; 9():926. PubMed ID: 29765374
[TBL] [Abstract][Full Text] [Related]
11. Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.
Rebmann V; Schütt P; Brandhorst D; Opalka B; Moritz T; Nowrousian MR; Grosse-Wilde H
Clin Immunol; 2007 Apr; 123(1):114-20. PubMed ID: 17218152
[TBL] [Abstract][Full Text] [Related]
12. [The roles of soluble MICA in immune escape of breast tumor].
Ye YB; Zhou ZF; Chen Q; Li JY; Chen X; Huang WW
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Sep; 24(9):904-7. PubMed ID: 18782524
[TBL] [Abstract][Full Text] [Related]
13. The predictive value of soluble major histocompatibility complex class I chain-related molecule A (MICA) levels on heart allograft rejection.
Suárez-Alvarez B; López-Vázquez A; Díaz-Molina B; Bernardo-Rodríguez MJ; Alvarez-López R; Pascual D; Astudillo A; Martínez-Borra J; Lambert JL; González S; López-Larrea C
Transplantation; 2006 Aug; 82(3):354-61. PubMed ID: 16906033
[TBL] [Abstract][Full Text] [Related]
14. IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.
Kloess S; Huenecke S; Piechulek D; Esser R; Koch J; Brehm C; Soerensen J; Gardlowski T; Brinkmann A; Bader P; Passweg J; Klingebiel T; Schwabe D; Koehl U
Eur J Immunol; 2010 Nov; 40(11):3255-67. PubMed ID: 21061445
[TBL] [Abstract][Full Text] [Related]
15. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients.
Salih HR; Goehlsdorf D; Steinle A
Hum Immunol; 2006 Mar; 67(3):188-95. PubMed ID: 16698441
[TBL] [Abstract][Full Text] [Related]
16. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
[TBL] [Abstract][Full Text] [Related]
17. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
18. High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma.
Samuels S; Ferns DM; Meijer D; van Straalen JP; Buist MR; Zijlmans HJ; Kenter GG; Jordanova ES
Tissue Antigens; 2015 Jun; 85(6):476-83. PubMed ID: 25871737
[TBL] [Abstract][Full Text] [Related]
19. The soluble major histocompatibility complex class I-related chain A protein reduced NKG2D expression on natural killer and T cells from patients with prolactinoma and non-secreting pituitary adenoma.
Ma L; Li G; Su Y; He Q; Zhang C; Zhang J
J Clin Neurosci; 2010 Feb; 17(2):241-7. PubMed ID: 20045334
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
